Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

fludarabine 19Cyclophosphamide 19fludarabine phosphate 16Azacitidine 15Tacrolimus 13Melphalan 13venetoclax 11Cytarabine 10Busulfan 10Whole-Body Irradiation 9Thiotepa 9Mycophenolic Acid 9Stem Cell Transplantation 7Peripheral Blood Stem Cell Transplantation 7Decitabine 7decitabine and cedazuridine drug combination 6Methotrexate 6Granulocyte Colony-Stimulating Factor 6Specimen Handling 5Sirolimus 5CPX-351 5AP 1903 reagent 5thymoglobulin 4Vorinostat 4Mesna 4Injections 4Daunorubicin 4Biopsy 4Ipilimumab 3Filgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Myelodysplastic Syndromes × seclidemstat × Clear all
NCT04734990 2026-04-02

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
24 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡